NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients
Table 1
Patients characteristics.
All patients ()
Macrovascular complications ()
Microvascular complications ()
Male genderc
105 (58.0)
29 (63.0)
0.423d
23 (67.6)
0.206d
Age (years)
64.0 (58.5–70.5)
64.0 (58.8–72.3)
0.495
64.0 (58.0–75.3)
0.251
Duration of T2D (years)
11.0 (6.0–17.0)
16.0 (7.0–23.5)
0.003
20.5 (11.0–27.0)
0.000
HbA1c (%) [mmol/mol]
6.9 (6.3–7.6) [52 (45–60)]
6.7 (5.9–7.4) [50 (41–57)]
0.143
6.5 (5.8–7.7) [48 (40–61)]
0.020
BMI (kg/m2)
30.0 (28.0–33.3)
30.0 (27.0–33.1)
0.741
29 (25.8–32.4)
0.191
Blood pressure systolic (mmHg)
135.0 (130.0–145.0)
140.0 (128.8–150.5)
0.257
139.0 (119.3–149.0)
0.759
Blood pressure diastolic (mmHg)
80.0 (70.0–80.0)
75.0 (65.8–80.0)
0.014
72.0 (63.0–80.0)
0.000
Total cholesterol (mmol/L)
4.2 (3.5–5.0)
3.9 (3.1–4.5)
0.004
3.7 (2.9–4.7)
0.002
LDL cholesterol (mmol/L)
2.4 (1.9–3.1)
2.3 (1.5–2.7)
0.047
2.0 (1.5–2.4)
0.004
HDL cholesterol (mmol/L)
1.1 (1.0–1.4)
1.1 (0.9–1.3)
0.009
1.1 (0.9–1.4)
0.323
TAG (mmol/L)
1.6 (1.2–2.4)
1.7 (1.1–2.2)
0.587
1.3 (0.9–2.1)
0.046
Comparison between patients with and without macrovascular complications. bComparison between patients with and without microvascular complications. Data are shown as median (25%–75%), except for c (%). values were calculated using Mann-Whitney test, except for dchi square test.